141 related articles for article (PubMed ID: 16715360)
1. Nontoxic suramin as a chemosensitizer in patients: dosing nomogram development.
Chen D; Song SH; Wientjes MG; Yeh TK; Zhao L; Villalona-Calero M; Otterson GA; Jensen R; Grever M; Murgo AJ; Au JL
Pharm Res; 2006 Jun; 23(6):1265-74. PubMed ID: 16715360
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of low-dose suramin as a chemosensitizer in patients with advanced non-small cell lung cancer.
Villalona-Calero MA; Wientjes MG; Otterson GA; Kanter S; Young D; Murgo AJ; Fischer B; DeHoff C; Chen D; Yeh TK; Song S; Grever M; Au JL
Clin Cancer Res; 2003 Aug; 9(9):3303-11. PubMed ID: 12960116
[TBL] [Abstract][Full Text] [Related]
3. Noncytotoxic suramin as a chemosensitizer in patients with advanced non-small-cell lung cancer: a phase II study.
Villalona-Calero MA; Otterson GA; Wientjes MG; Weber F; Bekaii-Saab T; Young D; Murgo AJ; Jensen R; Yeh TK; Wei Y; Zhang Y; Eng C; Grever M; Au JL
Ann Oncol; 2008 Nov; 19(11):1903-9. PubMed ID: 18632723
[TBL] [Abstract][Full Text] [Related]
4. Nontoxic suramin treatments enhance docetaxel activity in chemotherapy-pretreated non-small cell lung xenograft tumors.
Lu Z; Wientjes TS; Au JL
Pharm Res; 2005 Jul; 22(7):1069-78. PubMed ID: 16028007
[TBL] [Abstract][Full Text] [Related]
5. Phase I clinical trial of the novel platin complex dicycloplatin: clinical and pharmacokinetic results.
Li S; Huang H; Liao H; Zhan J; Guo Y; Zou BY; Jiang WQ; Guan ZZ; Yang XQ
Int J Clin Pharmacol Ther; 2013 Feb; 51(2):96-105. PubMed ID: 23127487
[TBL] [Abstract][Full Text] [Related]
6. A phase I pharmacokinetic study of bexarotene with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC).
Rodon J; Jacobs CD; Chu Q; Rowinsky EK; Lopez-Anaya A; Takimoto CH; Wakelee HA
Cancer Chemother Pharmacol; 2012 Mar; 69(3):825-34. PubMed ID: 22057853
[TBL] [Abstract][Full Text] [Related]
7. Suramin: development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentration in patients with prostate cancer.
Jodrell DI; Reyno LM; Sridhara R; Eisenberger MA; Tkaczuk KH; Zuhowski EG; Sinibaldi VJ; Novak MJ; Egorin MJ
J Clin Oncol; 1994 Jan; 12(1):166-75. PubMed ID: 8270974
[TBL] [Abstract][Full Text] [Related]
8. Suramin as a chemosensitizer: oral pharmacokinetics in rats.
Ogden A; Wientjes MG; Au JL
Pharm Res; 2004 Nov; 21(11):2058-63. PubMed ID: 15587928
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of biweekly paclitaxel and carboplatin for frail patients with advanced non-small cell lung cancer.
Yanagitani N; Tsuchiya S; Kaira K; Sunaga N; Tsuchiya Y; Sato K; Watanabe S; Nomura S; Sakai S; Saito R; Mori M
Am J Clin Oncol; 2007 Oct; 30(5):487-91. PubMed ID: 17921708
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetic analysis of patritumab, a HER3 inhibitor, in subjects with advanced non-small cell lung cancer (NSCLC) or solid tumors.
Yoshiba S; Jansen M; Matsushima N; Chen S; Mendell J
Cancer Chemother Pharmacol; 2016 May; 77(5):987-96. PubMed ID: 27017616
[TBL] [Abstract][Full Text] [Related]
11. Paclitaxel (1-hour) and carboplatin (area under the concentration-time curve 7.5) in advanced non-small cell lung cancer: a phase II study of the Fox Chase Cancer Center and its network.
Langer CJ; Millenson M; Rosvold E; Litwin S; McAleer CA; Bonjo CA; Ozols R
Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-81-S12-88. PubMed ID: 9331128
[TBL] [Abstract][Full Text] [Related]
12. Phase I evaluation of low-dose suramin as chemosensitizer of doxorubicin in dogs with naturally occurring cancers.
Kosarek CE; Hu X; Couto CG; Kisseberth WC; Green EM; Au JL; Wientjes MG
J Vet Intern Med; 2006; 20(5):1172-7. PubMed ID: 17063712
[TBL] [Abstract][Full Text] [Related]
13. A phase I study of suramin with once- or twice-monthly dosing in patients with advanced cancer.
Ryan CW; Vokes EE; Vogelzang NJ; Janisch L; Kobayashi K; Ratain MJ
Cancer Chemother Pharmacol; 2002 Jul; 50(1):1-5. PubMed ID: 12111104
[TBL] [Abstract][Full Text] [Related]
14. Sequence effect of docetaxel and carboplatin on toxicity, tumor response and pharmacokinetics in non-small-cell lung cancer patients: a phase I study of two sequences.
Ando M; Saka H; Ando Y; Minami H; Kuzuya T; Yamamoto M; Watanabe A; Sakai S; Shimokata K; Hasegawa Y
Cancer Chemother Pharmacol; 2005 Jun; 55(6):552-8. PubMed ID: 15856233
[TBL] [Abstract][Full Text] [Related]
15. A feasibility study of postoperative adjuvant therapy of carboplatin and weekly paclitaxel for completely resected non-small cell lung cancer.
Yamashita Y; Kataoka K; Ishida T; Matsuura M; Seno N; Mukaida H; Miyahara E; Miyata Y; Okita R; Shimizu K; Watari M; Okumichi T; Okada M
J Thorac Oncol; 2008 Jun; 3(6):612-6. PubMed ID: 18520800
[TBL] [Abstract][Full Text] [Related]
16. Phase I and pharmacokinetic study of carboplatin and paclitaxel with a biweekly schedule in patients with advanced non-small-cell lung cancer.
Ichiki M; Gohara R; Fujiki R; Hoashi S; Rikimaru T; Aizawa H
Cancer Chemother Pharmacol; 2003 Jul; 52(1):67-72. PubMed ID: 12743738
[TBL] [Abstract][Full Text] [Related]
17. High-dose therapy with carboplatin and paclitaxel in non-small cell lung cancer.
Socinski MA; Shea TC
Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-45-S12-51. PubMed ID: 9331121
[TBL] [Abstract][Full Text] [Related]
18. A phase I trial of paclitaxel plus carboplatin in untreated patients with advanced non-small cell lung cancer.
Kelly K; Pan Z; Murphy J; Huffman DH; Bunn PA
Clin Cancer Res; 1997 Jul; 3(7):1117-23. PubMed ID: 9815791
[TBL] [Abstract][Full Text] [Related]
19. A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC).
Cohen RB; Langer CJ; Simon GR; Eisenberg PD; Hainsworth JD; Madajewicz S; Cosgriff TM; Pierce K; Xu H; Liau K; Healey D
Cancer Chemother Pharmacol; 2007 Jun; 60(1):81-9. PubMed ID: 17031646
[TBL] [Abstract][Full Text] [Related]
20. Sequential versus concurrent paclitaxel and carboplatin for the treatment of advanced non-small cell lung cancer in elderly patients and patients with poor performance status: results of two Phase II, multicenter trials.
Marsland TA; Garfield DH; Khan MM; Look RM; Boehm KA; Asmar L
Lung Cancer; 2005 Jan; 47(1):111-20. PubMed ID: 15603861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]